Detect Range: 0.06 - 4.0 ng/mL
Sensitivity: 15pg/mL
Sample Type: Cell culture supernatant, serum, plasma (EDTA, citrate, heparin)
Sample Volume: 20 uL
Assay Time: 3 hour
Detection method: Colorimetric
Transforming growth factor (TGF), a 'factor' that promoted the transformation of cultured fibroblasts into a tumor-like phenotype, was subsequently found to be more of a tumor suppressor than tumor promoter and to be a mixture of two proteins, TGF-α and TGF-β. These molecules are members of a superfamily that includes TGF-β1 through 5, bone morphogenic proteins, activins and inhibins. It plays a critical role in cellular growth, development, differentiation, proliferation, extracellular matrix (ECM) synthesis and degradation, control of mesenchymal-epithelial interactions during embryogenesis, immune modulation, apoptosis, cell cycle progression, angiogenesis, adhesion and migration and leukocyte chemotaxis.
Originally, TGF-β1 was separated from platelets and later found that TGF-β1 can be expressed in many organizations. Human TGF-β1 is a 25kDa, disulfide-linked, non-glycosylated homodimer. Biological activity of TGF-β1 is regulated by a number of receptors, including receptor I (53-65KD), receptor II (83-110KD), receptor III (250-310KD), receptor-IV (60KD) and receptor V (400KD).
TGF-β1 is the key mediator in the pathophysiology of tissue repair and human fibrogenesis: balance between production and degradation of type I collagen, and fibrosis and scarring in organ and tissue. TGF-β1 exhibits important immunoregulatory features of partially adverse character: TGF-β1 inhibits B and T cell proliferation, differentiation and antibody production as well as maturation and activation of macrophages. TGF-β1 is synthesized, with only a few exceptions, by virtually all cells, and TGF receptors are expressed by all cells. TGF-β affects nearly every physiological process in some way; its systemic and cell-specific activities are too complicated to review here. There are, however, three fundamental activities: TGF-β1 modulates cell proliferation, generally as a suppressor; TGF-β1 enhances the deposition of extracellular matrix through promotion of synthesis and inhibition of degradation; TGF-β1 is immunosuppressive through a variety of mechanisms. The specific action of TGF-β on a particular cell depends on the exact circumstances of that cell's environment.
Kingsley, D.M. (1994) Genes Dev. 8:133.
Javelaud, D. and A. Mauviel (2004) Int. J. Biochem. Cell Biol. 36:1161.
Chang, H. et al. (2002) Endocr. Rev. 23:787.
Kondaiah, P. et al. (1988) J. Biol. Chem. 263:18313.
Clark, D.A. and R. Coker (1998) Int. J. Biochem. Cell Biol. 30:293.
Qian, S.W. et al. (1990) Nucleic Acids Res. 18:3059.
Derynack, R. et al. (1986) J. Biol. Chem. 261:4377.
Dubois, C.M. et al. (1995) J. Biol. Chem. 270:10618.
Manning, A.M. et al. (1995) Gene 155:307.
Brunner, A.M. et al. (1989) J. Biol. Chem. 264:13660.
Mittl, P.R.E. et al. (1996) Protein Sci. 5:1261.
Gray, A.M. and A.J. Mason (1990) Science 247:1328.
Oklu, R. and R. Hesketh (2000) Biochem. J. 352:601.
Saharinen, J. et al. (1996) EMBO J. 15:245.
Mangasser-Stephan, K. and A.M. Gressner (1999) Cell Tissue Res. 297:363.
Koli, K. et al. (2001) J. Cell Sci. 114:2869.
Yang, L. et al. (2000) Wound Rep. Reg. 8:538.
Pedrozo, H.A. et al. (1999) Endocrinology 140:5806.
Yu, Q. and I. Stamenkovic (2000) Genes Dev. 14:163.
Maeda, S. et al. (2001) J. Bone Miner. Res. 16:1281.
Munger, J.S. et al. (1999) Cell 96:319.
Derynck, R. et al. (1985) Nature 316:701.
Derynck, R. and X-H. Feng (1997) Biochim. Biophys. Acta 1333:F105.
Ten Dijke, P. et al. (1996) Curr. Opin. Cell. Biol. 8:139.
Chai, Y. et al. (2003) Crit. Rev. Oral Biol. Med. 14:78.
de Caestecker, M. et al. (2004) Cytokine Growth Factor Rev. 15:1.
My Review
© 2017, AbSci All Rights Reserved. E-mail: info@abscitech.com
南京川博生物技术有限公司版权所有
苏B1-20150380 苏ICP备15009006号-1